ME-344

ME-344 is an Isoflavone. ME-344 increases mitochondrial ROS generation. ME-344 inhibits tubulin polymerization. ME-344 inhibits HO-1 and impacts its mitochondrial translocation. ME-344 induces Apoptosis through Caspase 3 activation. ME-344 synergizes with Vinblastine in leukemia cells. ME-344 displays anti-tumor activity against leukemia and lung tumor. ME-344 can be used in the research of lung cancer, acute myeloid leukemia, and HER2-negative breast cancer^[1][2][3][4]. In Vitro:ME-344 (24 h) induces apoptosis in sensitive H460 and SHP-77 human lung cancer cells via activation of Caspase 3 and subsequent cleavage of PARP^[1].
ME-344 (10-10000 nM; 72 h) is cytotoxic to NB4, U937, K562, OCI-AML2, KG1a, HL-60, and TEX leukemia cell lines with IC₅₀ values ranging from 70 to 260 nM after 72 h of treatment^[2].
ME-344 (10 μM) potently inhibits tubulin polymerization in a cell-free biochemical assay^[2].
ME-344 (8 h) suppresses the de novo purine biosynthesis pathway in MV4-11 AML cells after 8 h of treatment, significantly reducing levels of AICAR and IMP^[4]. In Vivo:ME-344 (50-100 mg/kg; i.p.; every other day; 11 days) produces dose-dependent anti-tumor efficacy in a leukemia xenograft mouse model^[2].